SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328601. A total of 60 filers reported holding SUNESIS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q1 2016 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q4 2015 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q3 2015 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q2 2015 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q1 2015 | $0 | – | 141 | 0.0% | 0.00% | – |
| Q4 2014 | $0 | -100.0% | 141 | 0.0% | 0.00% | -100.0% |
| Q3 2014 | $1,000 | – | 141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 3,136,000 | $7,997,000 | 1.56% |
| Healthcare Value Capital, LLC | 200,000 | $510,000 | 0.93% |
| DSC Advisors, L.P. | 450,000 | $1,148,000 | 0.33% |
| Alden Global Capital Ltd | 188,200 | $480,000 | 0.12% |
| Perceptive Advisors | 500,000 | $1,275,000 | 0.11% |
| Baker Brothers Advisors | 3,200,000 | $8,160,000 | 0.08% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 653,970 | $1,668,000 | 0.07% |
| BALYASNY ASSET MANAGEMENT L.P. | 2,346,948 | $5,985,000 | 0.06% |
| Visium Asset Management, LP | 1,528,356 | $3,898,000 | 0.06% |
| Northeast Financial Consultants Inc | 11,000 | $28,000 | 0.02% |